Cue Biopharma, a clinical-stage biopharmaceutical firm, is developing injectable biologics intended to selectively engage and modulate tumor-specific T cells in the body to treat cancers, chronic infectious diseases, and autoimmune diseases. Their lead drug candidate is CUE-101, a fusion protein biologic aimed at activating antigen-specific T cells for human papilloma virus-driven cancers. Additionally, the company is developing CUE-102 and CUE-103, which target Wilms' Tumor 1 protein and Immuno-STAT, respectively. The firm also has programs for Neo-STAT and RDI-STAT outside of oncology. Cue has partnered with Merck Sharp & Dohme Corp. to research and develop its proprietary biologics for a variety of autoimmune disease indications, as well as with LG Chem to develop Immuno-STATs focused on the field of oncology. The company changed its name from Imagen Biopharma to Cue Biopharma in October 2016 and is based in Boston, Massachusetts.
Cue Biopharma's ticker is CUE
The company's shares trade on the ASX stock exchange
They are based in Melbourne, Australia
There are 11-50 employees working at Cue Biopharma
It is cuebiopharma.com
Cue Biopharma is in the Energy sector